Entries by CAPTIS

WuXi ATU and GeneMedicine sign development and manufacturing agreement for oncolytic virus products

This is the first international Chemistry, Manufacturing and Controls (CMC) development and manufacturing project empowered by the Oncolytic Virus contract development and manufacturing organization (CDMO) platform, which has The post WuXi ATU and GeneMedicine sign development and manufacturing agreement for oncolytic virus products appeared first on Pharmaceutical Business review.

Verrica Pharmaceuticals announces FDA filing acceptance of NDA for VP-102 to treat molluscum contagiosum

“There are no FDA-approved treatments currently available to patients diagnosed with molluscum, the majority of whom are children, leaving caregivers to choose between a wait-and-see approach or treatments The post Verrica Pharmaceuticals announces FDA filing acceptance of NDA for VP-102 to treat molluscum contagiosum appeared first on Pharmaceutical Business review.

Evofem Biosciences resubmits new drug application to US FDA for Amphora for the prevention of pregnancy

“Today’s submission represents a significant step forward for Evofem and for the millions of women who are dissatisfied with their current contraceptive options and are eagerly awaiting a The post Evofem Biosciences resubmits new drug application to US FDA for Amphora for the prevention of pregnancy appeared first on Pharmaceutical Business review.

Lonza and DiNAQOR announce strategic collaboration to advance gene therapy programs for patients with monogenic cardiomyopathies

Under the terms of the collaboration, Lonza will provide DiNAQOR preclinical, clinical and commercial production support for the company’s lead preclinical program DiNA-001, an adeno-associated virus (AAV) gene therapy program The post Lonza and DiNAQOR announce strategic collaboration to advance gene therapy programs for patients with monogenic cardiomyopathies appeared first on Pharmaceutical Business review.

FDA approves Oxbryta (Voxelotor), the first medicine specifically targeting the root cause of sickle cell disease

Oxbryta, an oral therapy taken once daily, is the first approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD.2,3 The medicine is expected to The post FDA approves Oxbryta (Voxelotor), the first medicine specifically targeting the root cause of sickle cell disease appeared first on Pharmaceutical Business review.

Asahi Kasei to acquire Veloxis Pharmaceuticals for $1.3bn

The Japanese conglomerate plans to acquire Veloxis Pharmaceuticals through its Danish subsidiary Asahi Kasei Pharma Denmark in a move to accelerate its transformation into a global healthcare company. The post Asahi Kasei to acquire Veloxis Pharmaceuticals for $1.3bn appeared first on Pharmaceutical Business review.

CARB-X funds VenatoRx to support development of new class of oral antibiotics to treat multi-drug-resistant gonorrhoea

Health officials have identified MDR gonorrhea, a sexually transmitted bacteria, as an urgent global public health threat, exacerbated by limited diagnostics and treatment options. Each year, according to The post CARB-X funds VenatoRx to support development of new class of oral antibiotics to treat multi-drug-resistant gonorrhoea appeared first on Pharmaceutical Business review.